Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT03711422 2022-06-14

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Phase 1 Terminated

2 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms

NCT02451553 2022-06-07

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

41 enrolled

Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

22 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02423525 2022-03-10

Safety Study of Afatinib for Brain Cancer

24 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Meningioma, Oligodendroglioma, Meningeal Carcinomatosis

NCT04448379 2020-12-28

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Phase 1 Unknown

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT01679405 2019-09-06

BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer

Phase 1 Terminated

9 enrolled 12 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03652233 2019-06-20

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Carcinoma, Squamous Cell

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

30 enrolled

Lung Neoplasms, Neoplasms

NCT00977431 2019-02-18

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

36 enrolled 16 charts

CNS

Glioblastoma

NCT01206816 2019-02-01

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

57 enrolled 19 charts

Neoplasms

NCT02975141 2018-08-13

AFFECT

Phase 1 Unknown

12 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02216617 2017-10-27

TAPIS

8 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01721525 2017-10-25

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

10 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02020577 2017-06-22

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

58 enrolled 13 charts

Neoplasms

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

83 enrolled 42 charts

Neoplasms

NCT00993499 2015-10-07

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

44 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT01090011 2015-10-02

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

171 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT00998296 2015-08-19

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

70 enrolled 25 charts

Neoplasms

NCT02171663 2015-01-28

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

43 enrolled

Neoplasms

NCT02171637 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

38 enrolled

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

40 enrolled

Neoplasms

NCT02171702 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

53 enrolled

Neoplasms

NCT02171728 2014-06-24

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

30 enrolled

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

31 enrolled

Neoplasms

NCT01169675 2014-06-09

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

53 enrolled 15 charts

Neoplasms

NCT01836341 2013-12-19

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

28 enrolled